Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/17/2005US20050058623 Use of gp130 activators in diabetic neuropathy
03/17/2005US20050058622 Preconditioning, ablation compound such as interleukins, colony stimulating factor
03/17/2005US20050058615 Process for cleaning bovine teats
03/17/2005US20050058614 Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
03/17/2005US20050058611 Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
03/17/2005US20050058606 Stable drug solution for aerosol administering; contining acid
03/17/2005US20050058605 gas or air filled microballoons in aqueous suspension; imaging contrast agent; ultrasonic echography
03/17/2005US20050058600 Administering; dosage; detection response; benign prostate hyperplasia; acne
03/17/2005DE69822327T2 Transdermales arzneistoff-abgabesystem für ein entzündungshemmendes analgetisches mittel enthaltend diclofenac diethylammonium salz, und verfahren zu dessen herstellung The transdermal drug-delivery system-containing medium for anti-inflammatory analgesic diclofenac diethylammonium salt, and process for its manufacture
03/17/2005DE10339532A1 New delta-15-D-homosteroid compounds are androgens used in hormone replacement therapy, fertility control or treatment of hormonally induced diseases e.g. breast cancer
03/17/2005DE10338407A1 Neue Inhalationspulver enthaltend den CGRP-Antagonisten New inhalable powders containing the CGRP antagonist 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
03/17/2005DE10338403A1 Pulverformulierung, enthaltend den CGRP-Antagonisten Powder formulation comprising the CGRP-antagonists 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum Process for its preparation and its use as Inhalativum
03/17/2005DE10338402A1 Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum Spray-dried, amorphous BIBN 4096, process for its preparation and its use as Inhalativum
03/17/2005DE10337863A1 Verwendung von Chromen-4-on-Derivaten The use of chromene-4-one derivatives
03/17/2005DE10337761A1 Phosphororganische 4-Iminohydantoinderivate Organophosphorus 4-Iminohydantoinderivate
03/17/2005DE10337191A1 Neue Verwendung von Chinolon-Antibiotika New use of quinolone antibiotics
03/17/2005DE10337186A1 Wässrige Wirkstoff-Lösung Aqueous drug solution
03/17/2005DE10337074A1 Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen Use of inhibitors of enzymes with activities of aminopeptidase N and / or of dipeptidyl peptidase IV and pharmaceutical preparations thereof for the treatment and prevention of chronic neurodegenerative diseases
03/17/2005CA2746516A1 Non-polar photosensitizer formulations for photodynamic therapy
03/17/2005CA2741575A1 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/17/2005CA2741412A1 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/17/2005CA2657076A1 Process for the preparation of rosuvastatin calcium
03/17/2005CA2579609A1 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
03/17/2005CA2579608A1 Spiro compounds and methods for the modulation of chemokine receptor activity
03/17/2005CA2572750A1 Heterobicyclic compounds as pharmaceutically active agents
03/17/2005CA2549465A1 New salts of omeprazole and esomeprazole i
03/17/2005CA2546823A1 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives
03/17/2005CA2542339A1 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
03/17/2005CA2541385A1 Nanoparticulate probe for in vivo monitoring of tissue oxygenation
03/17/2005CA2538820A1 Cytokine inhibitors
03/17/2005CA2538813A1 Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same
03/17/2005CA2538382A1 Antimicrobial compositions and methods
03/17/2005CA2538372A1 Calixarenes as inhibitors of protein kinase b
03/17/2005CA2538169A1 Transition state analog inhibitors of ricin a-chain
03/17/2005CA2538159A1 Polyamine-metal chelator conjugates
03/17/2005CA2538135A1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005CA2537976A1 Ozonation products of cholesterol for the treatment and prevention of artherosclerosis and/or cardiovascular diseases
03/17/2005CA2537883A1 Substituted bicyclic quinazolin-4-ylamine derivatives
03/17/2005CA2537878A1 Polymorphic nucleoside compounds
03/17/2005CA2537829A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
03/17/2005CA2537765A1 Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
03/17/2005CA2537763A1 Treatment for cd5+ b cell lymphoma
03/17/2005CA2537757A1 The combination of a serotonin reuptake inhibitor and amoxapine
03/17/2005CA2537752A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process
03/17/2005CA2537747A1 The combination of a serotonin reuptake inhibitor and loxapine
03/17/2005CA2537746A1 Erg channel openers for the treatment of cardiac arrhythmias
03/17/2005CA2537744A1 Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters
03/17/2005CA2537677A1 Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics
03/17/2005CA2537545A1 Thienopyrroles as antiviral agents
03/17/2005CA2537536A1 Process for the preparation of renzapride and intermediates thereof
03/17/2005CA2537493A1 A radioisotope-chitosan complex for treatment of prostate cancer
03/17/2005CA2537488A1 Nicotine formulations and use thereof
03/17/2005CA2537480A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
03/17/2005CA2537321A1 Heterocyclic inhibitors of mek and methods of use thereof
03/17/2005CA2537292A1 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005CA2537290A1 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
03/17/2005CA2537281A1 Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
03/17/2005CA2537252A1 Cyclohexyl prostaglandin analogs as ep4-receptor agonists
03/17/2005CA2537230A1 Use of pde4 inhibitors for the treatment of diabetes mellitus
03/17/2005CA2537226A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
03/17/2005CA2537098A1 N3 alkylated benzimidazole derivatives as mek inhibitors
03/17/2005CA2537097A1 Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
03/17/2005CA2537096A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
03/17/2005CA2536975A1 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
03/17/2005CA2536967A1 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/17/2005CA2536930A1 Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents
03/17/2005CA2536927A1 Guanidine derivatives
03/17/2005CA2536874A1 Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
03/17/2005CA2536775A1 Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
03/17/2005CA2536669A1 Methods for intradermal delivery of therapeutics agents
03/17/2005CA2536175A1 Pharmaceutical compositions and method of using levodopa and carbidopa
03/17/2005CA2535983A1 New salts of omeprazole and esomeprazole ii
03/17/2005CA2535889A1 Combination methods of treating cancer
03/17/2005CA2535780A1 Antibiotic product, use and formulation thereof
03/17/2005CA2535744A1 Piperazines as oxytocin agonists
03/17/2005CA2535529A1 Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions
03/17/2005CA2532941A1 Composition and method for facilitating bone healing
03/17/2005CA2532161A1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases
03/17/2005CA2481903A1 Decongestant/antihistaminic/expectorant compositions
03/16/2005EP1514942A1 Method of searching substane having antidiabetic activity
03/16/2005EP1514929A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells
03/16/2005EP1514877A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
03/16/2005EP1514872A1 Phosphorylated glyceryl ether aluminium salts
03/16/2005EP1514871A1 Dispiro 1,2,4 - trioxolane antimalarials
03/16/2005EP1514870A1 Prodrug and process for producing the same
03/16/2005EP1514867A2 Substituted phenyl derivatives, their preparation and use
03/16/2005EP1514560A1 Process for producing block copolymer/drug composite
03/16/2005EP1514559A1 Arylpiperazines having activity at the serotonin 1a receptor
03/16/2005EP1514557A1 Preventives/remedies for bone and joint diseases
03/16/2005EP1514554A1 Oral composition based on natural substances useful in the maintenance of the correct hydration of the skin
03/16/2005EP1514552A1 Novel fused imidazole derivative
03/16/2005EP1514551A1 Antiinflammatory agent, agent for preventing/ameliorating allergic diseases and functional food
03/16/2005EP1514550A2 Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
03/16/2005EP1514549A1 Powdery respiratory tonic composition
03/16/2005EP1514548A2 Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension
03/16/2005EP1514547A1 Controlled-release drug composition
03/16/2005EP1514546A1 Medicament compositions based on tiotropium salts and on salmeterol salts
03/16/2005EP1514545A1 Use of tolperisone for the treatment of spasms of organes consisting essentially of smooth muscles.
03/16/2005EP1514544A1 Antiallergic
03/16/2005EP1514543A1 Combination therapy comprising atorvastatin and an antihypertensive agent
1 ... 4752 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 ... 7860